ReviewHypertension research : official journal of the Japanese Society of Hypertension2025
Risk management of cardiovascular disease in older patients with diabetes.
Review in Hypertension research : official journal of the Japanese Society of Hypertension, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cardiovascular disease risk and associated factors among people with hypertension in the West Bank, Palestine.Frontiers in cardiovascular medicine · 2026Article
- GLP-1 Receptor Agonist Therapy in Older Adults with Diabetes: A Qualitative Analysis of Phase 4 ClinicalTrials.gov Studies.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The number of older patients with diabetes has been increasing due to Japan's rapidly aging population. As aging and diabetes are independent risk factors for cardiovascular disease, older adults face a higher risk of cardiovascular disease, with the incidence of heart failure and stroke increasing significantly with age. Preventing cardiovascular events is critical for this population to maintain their activities of daily living and improve their quality of life. To achieve this challenging purpose, it is essential to prioritize the use of glucose-lowering medications with proven cardiovascular benefits and to comprehensively manage risk factors, including blood pressure, as with younger patients. However, considering the vulnerability and divergent health status of older patients, population-specific effects and precautions regarding medications, such as sodium-glucose cotransporter (SGLT) 2 inhibitors and glucagon-like peptide 1 receptor agonists (GLP-1RA) should be considered. In particular, we must deliberate their impact on frailty when administering these medications to this population. In this mini review, we discuss the characteristics of older patients with diabetes and update the evidence on the consistent efficacy and safety of SGLT2 inhibitors and GLP-1RA in older patients. In addition, recent clinical trials that examined the effect of stricter blood pressure control in older patients with diabetes have been reconsidered to accomplish comprehensive risk management for preventing cardiovascular disease. Heterogeneity of older patients with diabetes and principles of cardiovascular risk management in this population. SGLT2: sodium glucose cotransporter 2, GLP-1RA: glucagon-like peptide 1 receptor agonist.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.